Pacific Edge in holding mode as US Medicare decision nears

Pacific Edge in holding mode as US Medicare decision nears
Total laboratory use of Pacific Edge's Cxbladder tests in the US rose in the 2024 financial year but the growth rate slowed in the second half as the company reduced its sales team. (Image: Thinkstock)
Greg Hurrell
Pacific Edge says the 2024 finance year has been one of two halves, as it quickly switched from growth to capital preservation.That sudden change of focus came from a major setback with the possible loss of access to the US Medicare system which has been its largest customer.The company reported a loss of $29.5 million for the March 31 financial year, 9.5% bigger than 2023’s net loss, amid that slowing growth.MedicareThe company said it was prepared for all outcomes as it waited to see whether it would hang on to its Medicare deal, which...

More Markets

Radius Care's run continues as earnings jump 14%
Markets

Radius Care's run continues as earnings jump 14%

The small-cap aged care services company's shares have lifted 57% this year. 

Channel looks to raise $50m, inks deal with Fletcher subsidiary
Markets

Channel looks to raise $50m, inks deal with Fletcher subsidiary

Projects expected to deliver $120m in incremental revenue over 15-year period. 

Margaret Warrington appointed Summerset's CFO
Markets

Margaret Warrington appointed Summerset's CFO

Warrington will join the group in late February next year.